THIS MATERIAL IS A MARKETING COMMUNICATION.
From Innovation to Revolution: Chinese Biotech Industry
Biotechnology is the use of biological materials, such as proteins, antibodies, genes, and cells, to develop new drugs and treatments. It is not a new concept. Humans have been harnessing the power of organisms for thousands of years – bread making is an early example.
That said, recent advances have revolutionized our understanding of biosciences and may present the first legitimate possibility of treating illnesses once thought incurable or fatal.
Healthcare in China remains relatively under penetrated – more specifically, biotech-driven treatments account for only 12% of the country’s total drug market. However, this is set to change with the emergence of several key catalysts, which will have a significant impact on both companies and investors over the next decade. Most notably, these include the NMPA’s attempt to build a more transparent and efficient drug-approval system based on global standards. We also have seen shifts in the prescription mix that have an increasing focus on clinical benefits and the establishment of a more focused and dynamic, single-payer system.
This transformation is expected to alter the industry’s strategic focus from the development of generic drugs to the creation of new products. In turn, it will drive consolidation among generic manufacturers and see the emergence of a new breed of innovative biotech companies that will potentially provide significant economic returns on investment. Further details on these drivers are noted below.
A Gradual Evolution
There are risks, of course. The biotech sector requires substantial investment in research and development (“R&D”), and this outlay is not guaranteed to result in commercially successful products. But a significant number of Chinese biotech companies are seeking to mitigate R&D risks by developing so-called “me-too drugs,” which are closely related to existing products. Another low R&D risks’ development, named “me-better offerings,” could improve the existing treatments but can’t be classified as ‘new.’ As a result, we see cancer and other therapeutic categories, in particular, being driven into a more crowded space. However, we do expect a gradual evolution of R&D strategies into a best-in-class or first-in-class approach. This move will is expected to heighten innovation, ranging from contracted research and drug discovery to drug manufacturing in the Chinese market.
We should also point out that a biotech firm’s prospects are also vulnerable to changes in the regulatory environment, intensifying competition, and a rapidly evolving nature in technological progress. Intellectual property remains a concern, too. Furthermore, many companies are dependent on the ability to use and enforce intellectual property rights and patents, even if effective, the expiry of rights and licenses can have adverse financial consequences on those businesses.
What is Underpinning China’s Biotech Industry?
The aging society and the urbanization shift will continuously drive the demand for quality healthcare in China. There are over 400 million people who will be 60 years or above by 2030. Also, over 56% of the population now live in towns and cities. It is also worth noting that people’s ability to fund their healthcare costs is also increasing with the average disposable income of residents rising to Rmb 28,228 in 2018 (or US$4,097) – this is 54% higher than five years earlier.
From a health perspective, the charts below show that cancer incidence and diabetes prevalence will increase significantly beyond the ages of 50–60.
According to market analyst Frost & Sullivan, China’s biotech market is expected to grow to US$96 billion by 2023, from US$40 billion in 2018, that is an annual growth rate of 19%.
Several themes will drive the expansion of China’s biotech industry:
ACCESSIBILITY: As of April 2019, China’s drug authority, the NMPA, licensed 33 antibody/fusion protein-based therapies, including 21 imported and 12 domestic drugs. This number is still below US levels, where approximately 100 treatments received the green light but is still a notable improvement on the 21 approvals as of May 2018.
REIMBURSEMENT COVERAGE IS IMPROVING: From 2015–2017, a total of 18 monoclonal antibodies (mAbs) and fusion proteins were added to the National Reimbursement Drug List (NRDL) for the first time. The NRDL is a catalog of treatments that qualify for reimbursement under government-supported health insurance schemes. In 2018, the NMPA then only included 17 anti-cancer drugs in the NRDL. We expect this trend to continue as more therapies to gain approval.
A SHIFT IN THE PRESCRIPTION MIX: The growth of medical insurance funds is strictly controlled. But government initiatives aimed at reducing the amount spent on drugs that lack substantial evidence of clinical benefits, such as traditional Chinese medicine, which still accounts for 30% of total market share. These initiatives could create room for medical insurance spending on new therapies.
THE GROWING ADOPTION OF PHARMACOECONOMICS: The government agencies that administer the medical insurance system in China have begun to recognize the value of pharmacoeconomics (an all-round measure of drug efficiency) in assessing the cost-benefits of new therapies. Since 2017, the Ministry of Human Resources and Social Security of the People’s Republic of China (MOHRSS) has included pharmacoeconomic factors when deciding whether to bring the patent drugs into the NRDL catalog.
BIOSIMILARS DEVELOPMENT: Biosimilars, which are drugs closely related to existing treatments, are currently being developed by Chinese companies. These are potentially cheaper alternatives to those already produced by the big multinationals. China approved its first biosimilar (Henlius’ Rituximab for the treatment of non-Hodgkin lymphoma) in February 2019. More launches will potentially follow this in the second half of 2019 and throughout 2020, as over 150 biosimilar candidates are at different stages of clinical development.
Globally, biotech-driven drugs have seen significant growth over the past few decades. In 2018, seven out of the top ten bestselling products globally were biologic, including two innovative PD-1 treatments.
Improving Access to Capital
Key recent developments include (1) Changes to the Stock Exchange of Hong Kong’s listing rules for pre-revenue biotech companies and the China Securities Regulatory Commission’s new fast-track approval for the listing of high-tech ‘unicorns,’ and 2) Growing private equity and venture capital investment in biotech.
In the Future?
Over the longer term, China’s biotech business has the potential to go global, either by out-licensing to overseas markets or by developing assets in the US, EU and elsewhere. According to industry analyst China Bio, Chinese biotech companies made 164 cross-border licensing deals in 2018, more than double the 2013 figure. Furthermore, China is pursuing trials for one-quarter of its innovative assets overseas.
The country’s increasing dominance is also reflected in the number of biotechnology patents granted, rising from more than 1,000 (12% of the global total) in 2006 to more than 6,000 (27% of the world total) in 2016. In 2012, China even surpassed the US in this area.
Finally, China’s government has listed biotechnology as one of the ten critical sectors for development under its “Made in China 2025” industrial strategy. The authorities are improving the country’s regulatory framework, reforming the drug-approval process, and providing more explicit guidance for biosimilar developers.
Fact check: What are biologic drugs?
Biological drugs refer to products derived from living organisms or parts of living organisms, such as proteins, vaccines, blood components, and genes. A biologic drug differs from small single-molecule medicines – it is larger in terms of molecule size and more complex in structure.
This type of treatment has become more popular as new therapies in various diseases, such as cancer, autoimmune diseases, and endocrine system diseases, have been developed. The manufacture of biologics is very different from chemical manufacturing: microorganisms are normally used, so a suitable environment for growing these is essential.
THIS ARTICLE IS FOR EDUCATIONAL PURPOSES. NOT FOR SOLICITATION, OFFER OR RECOMMENDATION TO TRADE ANY SECURITIES.
This material is neither an offer to sell nor solicitation to buy a security to any person in any jurisdiction where such solicitation, offer, purchase or sale would be unlawful under the laws of that jurisdiction. Investment involves risk.
The information in this material is based on sources we believe to be reliable but we do not guarantee the accuracy of completeness of the information provided. This material has not been reviewed by SFC and shall only be circulated in countries where it is permitted.
This material is intended solely for your private use and shall not be reproduced or recirculated either in whole or in part, without the written permission of Mirae Asset Global Investments. This document has been prepared for presentation, illustration and discussion purposes only and is not legally binding. Whilst compiled from sources Mirae Asset Global Investments believes to be accurate, no representation, warranty, assurance or implication to the accuracy, completeness or adequacy from defect of any kind is made. The division, group, subsidiary or affiliate of Mirae Asset Global Investments which produced this document shall not be liable to the recipient or controlling shareholders of the recipient resulting from its use. The views and information discussed or referred in this report are as of the date of publication, are subject to change and may not reflect the current views of the writer(s). The views expressed represent an assessment of market conditions at a specific point in time, are to be treated as opinions only and should not be relied upon as investment advice regarding a particular investment or markets in general. In addition, the opinions expressed are those of the writer(s) and may differ from those of other Mirae Asset Global Investments’ investment professionals.
The provision of this document shall not be deemed as constituting any offer, acceptance, or promise of any further contract or amendment to any contract which may exist between the parties. It should not be distributed to any other party except with the written consent of Mirae Asset Global Investments. Nothing herein contained shall be construed as granting the recipient whether directly or indirectly or by implication, any license or right, under any copy right or intellectual property rights to use the information herein. This document may include reference data from third-party sources and Mirae Asset Global Investments has not conducted any audit, validation, or verification of such data. Mirae Asset Global Investments accepts no liability for any loss or damage of any kind resulting out of the unauthorized use of this document. Investment involves risk. Past performance figures are not indicative of future performance. Forward-looking statements are not guarantees of performance. The information presented is not intended to provide specific investment advice. Please carefully read through the offering documents and seek independent professional advice before you make any investment decision. Products, services, and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries, and/or distributors of Mirae Asset Global Investments as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.
Hong Kong: This material is prepared by Mirae Asset Global Investments (HK) Limited (Mirae HK). Mirae HK is regulated by the SFC (CE reference: ALK083).
Australia: The information contained on this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. By accessing this document and any information or content contained in it, you represent that you are a ‘wholesale client’ under the Corporations Act. This document is strictly for information purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. Further, this document should not be regarded by investors as a substitute for independent professional advice or the exercise of their own judgement. The contents of this document is prepared and maintained by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission. No part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGI HK. Copyright 2020. All rights reserved.
United Kingdom: This document does not explain all the risks involved in investing in the Fund and therefore you should ensure that you read the Prospectus and the Key Investor Information Documents (“KIID”) which contain further information including the applicable risk warnings. The taxation position affecting UK investors is outlined in the Prospectus. The Prospectus and KIID for the Fund are available free of charge from http://investments.miraeasset.eu, or from Mirae Asset Global Investments (UK) Ltd., 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom, telephone +44 (0)20 7715 9900.
This document has been approved for issue in the United Kingdom by Mirae Asset Global Investments (UK) Ltd, a company incorporated in England & Wales with registered number 06044802, and having its registered office at 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom. Mirae Asset Global Investments (UK) Ltd. is authorised and regulated by the Financial Conduct Authority with firm reference number 467535.
Staying Ahead with Mirae Asset’s Latest Insights
Disclaimer & Information for Investors
No distribution, solicitation or advice: This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service.
The views and information discussed or referred in this document are as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. In addition, the opinions expressed may differ from those of other Mirae Asset Global Investments’ investment professionals.
Investment involves risk: Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.
Sources: Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (“MAGI”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.
Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGI as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Information for EU investors pursuant to Regulation (EU) 2019/1156: This document is a marketing communication and is intended for Professional Investors only. A Prospectus is available for the Mirae Asset Global Discovery Fund (the “Company”) a société d'investissement à capital variable (SICAV) domiciled in Luxembourg structured as an umbrella with a number of sub-funds. Key Investor Information Documents (“KIIDs”) are available for each share class of each of the sub-funds of the Company.
The Company’s Prospectus and the KIIDs can be obtained from www.am.miraeasset.eu/fund-literature . The Prospectus is available in English, French, German, and Danish, while the KIIDs are available in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the “UCITS Directive”). Please refer to the Prospectus and the KIID before making any final investment decisions.
A summary of investor rights is available in English from www.am.miraeasset.eu/investor-rights-summary.
The sub-funds of the Company are currently notified for marketing into a number of EU Member States under the UCITS Directive. FundRock Management Company can terminate such notifications for any share class and/or sub-fund of the Company at any time using the process contained in Article 93a of the UCITS Directive.
Hong Kong: This document is intended for Hong Kong investors. Before making any investment decision to invest in the Fund, Investors should read the Fund’s Prospectus and the information for Hong Kong investors (of applicable) of the Fund for details and the risk factors. The individual and Mirae Asset Global Investments (Hong Kong) Limited may hold the individual securities mentioned. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Copyright 2021. All rights reserved. No part of this document may be reproduced in any form, or referred to in any other publication, without express written permission of Mirae Asset Global Investments (Hong Kong) Limited.